Day: August 7, 2022

Awilco Drilling PLC’s Second Quarter 2022 report will be released prior to market opening on Tuesday 9 August 2022. A digital presentation will be held the same day, Tuesday 9 August 2022, at 14:00 UK time (15:00pm CET / 09:00 EST). The presentation will be available for download on the Investor Relations section (go to “Press Releases”) at www.awilcodrilling.com prior to the meeting. There will be a Q&A session after the presentation. To join the digital meeting, please click this link or copy and paste the following address into your browser:https://teams.microsoft.com/l/meetup-join/19%3ameeting_ZDMxYjFlNjItZTBkZC00ZTIyLTg0OTAtYzIyMjUyMGVmY2Vl%40thread.v2/0?context=%7B%22Tid%22%3A%2213406330-ee57-43ad-9fa7-ea6e572899d4%22%2C%22Oid%22%3A%22458b2508-72ce-45ca-8967-b3180623e08e%22%2C%22IsBroadcastMeeting%22%3Atrue%2C%22role%22%3A%22a%22%7D&btype=a&role=a A...

In the ongoing GEMSTONE-301 Phase 3 study, sugemalimab, administered after treatment with either concurrent or sequential chemoradiotherapy, demonstrated a statistically significant improvement in progression-free survival versus placebo in patients with unresectable Stage III non-small cell lung cancer (NSCLC) There are currently no immunotherapy consolidation treatments in the U.S. or Europe approved for patients with unresectable Stage III NSCLC who have received sequential chemoradiotherapyCAMBRIDGE, Mass., Aug. 07, 2022 (GLOBE NEWSWIRE) — EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced a late-breaking oral presentation of updated data from the Phase 3 GEMSTONE-301 trial of sugemalimab in non-small...